ストックスクリーナーアプリを入手
0.7498
4.90%
-0.0386
前日終値:
$0.7884
開ける：
$0.78
24時間の取引高:
44,417
Relative Volume:
0.15
時価総額：
$10.02M
収益：
-
当期純損益:
$-58.92M
株価収益率:
-0.0164
EPS:
-45.8429
ネットキャッシュフロー:
$-401.10K
1週間 パフォーマンス:
-10.35%
1か月 パフォーマンス:
-3.54%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.74
$0.7884
1週間の範囲:
$0.74
$0.8325
52週間の値動き範囲:
$0.73
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
名前
Propanc Biopharma Inc
セクター
電話
61-03-9882-0780
住所
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
PPCB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.49 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.17 | 303.77M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.04 | 221.34M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.67 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.76 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc (PPCB) 最新ニュース
Propanc Biopharma Shares Gain After Seeking Patent Protection for New Cancer and Fibrosis Treatments - MSN
Propanc Biopharma Inc. (PPCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Propanc Biopharma, Inc. (PPCB) -6.3% in After-hours: Shares Slide Amid Investigation Announcement - Stocks Telegraph
Propanc Biopharma Investigates 'Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) targets fibrosis, cancer via PRP EMT research - Stock Titan
Views of Wall Street’s Leading Experts on Propanc Biopharma Inc - setenews.com
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga
Propanc Biopharma files patents for resistant cancer and fibrosis treatments By Investing.com - Investing.com Australia
Propanc Biopharma stock rises after filing for patents to treat resistant cancer By Investing.com - Investing.com South Africa
Propanc Biopharma stock rises after filing for patents to treat resistant cancer - Investing.com Australia
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - The Manila Times
Propanc Biopharma files patents for resistant cancer and fibrosis treatments - Investing.com
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant ... - Enidnews.com
Propanc Biopharma (Nasdaq: PPCB) moves to patent PRP use in fibrosis ahead of 2026 Phase 1b trial - Stock Titan
Propanc Biopharma secures up to $100 million private placement - MSN
Australian firm launches crypto treasury for the future of cancer drug - Proactive financial news
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) Raises $4M, Lists on Nasdaq, Sets $100M Facility - Stock Titan
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Propanc Biopharma Secures $1M Through Stock Sale - MSN
Propanc Biopharma Secures $100M Crypto Deal for Cancer Breakthrough - Analytics Insight
Propanc Biopharma Secures Up to $100M to Build Crypto Treasury and Advance Cancer Therapy Trials - Bitget
The time has not yet come to remove your chips from the table: Propanc Biopharma Inc (PPCB) - setenews.com
Propanc Biopharma (PPCB) Stock: Crypto Treasury Plan Triggers Massive Sell-Off - parameter.io
Propanc Biopharma (PPCB) Stock: Biotech Secures $100M Crypto Funding as Shares Tumble - Blockonomi
Propanc, The Australian Biotech, Turns To Crypto To Tackle Cancer - Bitcoinist.com
Propanc Biopharma (PPCB) Stock: Company Secures $100M Crypto Treasury Deal - CoinCentral
Propanc Biopharma secures up to $100 million investment from Hexstone By Investing.com - Investing.com Nigeria
Propanc Biopharma secures $1 million initial investment from Hexstone By Investing.com - Investing.com Nigeria
Propanc Biopharma Secures $100M to Build Crypto Treasury - Coinpaper
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5% - Bitget
Biopharma raises $100M for crypto treasury to back cancer treatment - TradingView
[8-K] Propanc Biopharma, Inc. Reports Material Event | PPCB SEC FilingForm 8-K - Stock Titan
Biotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push - TradingView
Propanc Biopharma, Inc. announced that it has received $1 million in funding from Hexstone Capital, LLC - MarketScreener
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) secures up to $100M to fund digital assets; $1M received - Stock Titan
Taking on analysts’ expectations and winning: Propanc Biopharma Inc (PPCB) - setenews.com
Propanc Biopharma plans digital asset company acquisitions By Investing.com - Investing.com Nigeria
Propanc Biopharma plans digital asset company acquisitions - Investing.com India
$100 Million Deal Positions This Microcap at the Crossroads of Biotech and Digital Finance - The Globe and Mail
Propanc Biopharma Inc (PPCB) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
1.12%
大文字化:
|
ボリューム (24 時間):